Evidence-generation program

An evidence-generation program is a coordinated plan for producing clinical, real-world, and economic data to support the value and positioning of a pharmaceutical product.

What is an evidence-generation program?

An evidence-generation program is a strategic framework used to plan, develop, and deliver data that demonstrates the clinical effectiveness, safety, economic value, and real-world impact of a pharmaceutical product. It includes both pre- and post-launch activities and may involve clinical trials, real-world evidence (RWE) studies, observational research, health economics and outcomes research (HEOR), and patient-reported outcomes (PROs). Programs are typically tailored to the needs of key stakeholders such as regulators, payers, providers, and patients.

Why are evidence-generation programs important?

Evidence-generation programs enable pharmaceutical companies to build a comprehensive value story, address stakeholder evidence requirements, and support market access and reimbursement. By generating relevant and credible data throughout the product lifecycle, companies can inform clinical decision-making, enhance competitive positioning, and meet evolving expectations for transparency, patient-centered outcomes, and long-term impact.

Linked Resource here?
No spam. Just the latest releases and tips, interesting articles, and exclusive interviews in your inbox every week.
Read about our privacy policy.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.